ERBB2 and breast carcinoma: Several past clinical trials have documented that LHRHas can be used as an alternative postoperative adjuvant therapy to chemotherapy in premenopausal women with HR+, human epidermal growth factor receptor 2 (HER2)-negative, and lymph node +/- breast cancer (7–13).